364 related articles for article (PubMed ID: 37451404)
1. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM; McNamee CJ; Toloza E; Negrao MV; Lin J; Shum E; Cummings AL; Kris MG; Sepesi B; Bara I; Kurtsikidze N; Schulze K; Ngiam C; Chaft JE
J Thorac Oncol; 2023 Nov; 18(11):1458-1477. PubMed ID: 37451404
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
3. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
5. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
Isaacs J; Stinchcombe TE
Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
[TBL] [Abstract][Full Text] [Related]
7. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
Godoy LA; Chen J; Ma W; Lally J; Toomey KA; Rajappa P; Sheridan R; Mahajan S; Stollenwerk N; Phan CT; Cheng D; Knebel RJ; Li T
Biomark Res; 2023 Jan; 11(1):7. PubMed ID: 36650586
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
9. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
West HJ; Kim JY
JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
[TBL] [Abstract][Full Text] [Related]
10. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
11. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
12. Combined modality treatment of non-small-cell lung cancer.
Westeel V; Depierre A
Am J Respir Med; 2003; 2(6):477-90. PubMed ID: 14719987
[TBL] [Abstract][Full Text] [Related]
13. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
Choong NW; Vokes EE
Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S98-104. PubMed ID: 16384544
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
Zhang C; Li SL; Nie Q; Dong S; Shao Y; Yang XN; Wu YL; Yang Y; Zhong WZ
J Thorac Oncol; 2019 Apr; 14(4):726-731. PubMed ID: 30408570
[TBL] [Abstract][Full Text] [Related]
16. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Sathiyapalan A; Baloush Z; Ellis PM
Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy in stages I to III non-small cell lung cancer.
Strauss GM
Chest; 1999 Dec; 116(6 Suppl):509S-516S. PubMed ID: 10619521
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S; Zhang W; Wu L; Wang W; Zhang P; ; Fang W; Xing W; Chen Q; Yang L; Mei J; Tan L; Sun X; Xu S; Hu X; Yu G; Yu D; Yang N; Chen Y; Shan J; Xing L; Tian H; Zhang X; Zhou M; Fang H; Wu G; Liu Y; Ye M; Cao L; Jiang J; Li X; Zhu L; Li D; Kang M; Zhong A; Chen K; Wu N; Sun Q; Ma H; Cai K; Wang C; Lin G; Zhu K; Zhang Y; Zhang X; Hu H; Zhang W; Chen J; Yang Z; Hang X; Hu J; Huang Y; Zhang Z; Zhang L; Zhang L; Liu L; Lin D; Zhang J; Chen G; Li Y; Zhu L; Wang W; Yu W; Cao D; Keegan P; Yao S
JAMA; 2024 Jan; 331(3):201-211. PubMed ID: 38227033
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
20. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
